[Intrathecal baclofen therapy: the selection of patients and short term results in five patients].
BACKGROUND
Intrathecal baclofen therapy (ITB) is a new tool in the integrated treatment of childhood spasticity. AIMS. We describe the eligibility and exclusion criteria used in the study and short term results of ITB therapy in our first five patients are also reported.


METHODS
Our sample of patients consisted of three females and two males aged between 14 and 17 years. Two of them were ambulant (one without help and the other with crutches), two were serious non ambulant tetraparetics and the other was in a wheelchair but minimally ambulant. All of them satisfied our eligibility criteria. The main aims set out were to improve walking in the three patients with less serious involvement and to reduce or eliminate the pain and enhance quality of life (QOL) in the two more seriously affected patients. In all cases, the Baclofen test was positive.


RESULTS
Follow up time was between 2 and 5 months. The objectives appear to have been accomplished, for the time being, in three patients: the two ambulant patients improved their capacity to walk and one male with serious spastic tetraparesis and pain no longer suffers from that pain and his QOL has improved. There were mild transient side effects in three patients.


CONCLUSIONS
The selection of patients, including the definition of realistic tailor made objectives, is an essential step in ITB therapy. Results in our series, in the short term, indicate that ITB therapy can be efficient in ambulant and non ambulant patients, and offers few side effects.
Gutiérrez-Solana
L G
LG
Servicio de Neurología Pediátrica. Hospital Universitario Niño Jesus, Madrid, España. med019243@saludalia.com
Ruiz-Falcó
M L
ML
Pérez-Díaz
C
C
D000293:Adolescent; D001418:Baclofen / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007278:Injections, Spinal; D008297:Male; D009128:Muscle Spasticity / Q000188:drug therapy*; D010146:Pain / Q000188:drug therapy; D011788:Quality of Life; D016896:Treatment Outcome
D001418:Baclofen